FOXN3 and acute myeloid leukemia: As shown in Figure 1, the FOXN3 mRNA levels in AML patients (median: 0.468, range: 0.000‐4.640) were significantly downregulated compared with those in the controls (median: 1.000, range: 0.214‐5.525) (P < .0001, Figure 1A).